159 related articles for article (PubMed ID: 35595128)
1. Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.
Pereson MJ; Amaya L; Neukam K; Baré P; Echegoyen N; Badano MN; Lucero A; Martelli A; Garcia GH; Videla C; Martínez AP; Di Lello FA
Clin Microbiol Infect; 2022 Oct; 28(10):1382-1388. PubMed ID: 35595128
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients.
Laham G; Martínez AP; Rojas Gimenez W; Amaya L; Abib A; Echegoyen N; Díaz C; Lucero A; Martelli A; Videla C; Neukam K; Di Lello FA
J Nephrol; 2023 Apr; 36(3):861-872. PubMed ID: 36152219
[TBL] [Abstract][Full Text] [Related]
3. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
4. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
7. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
Front Immunol; 2022; 13():917905. PubMed ID: 35799790
[TBL] [Abstract][Full Text] [Related]
8. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
Pascuale CA; Varese A; Ojeda DS; Pasinovich ME; Lopez L; Rossi AH; Rodriguez PE; Miglietta EA; ; Mazzitelli I; Di Diego Garcia F; Sanchez L; Rouco SO; Gonzalez Lopez Ledesma MM; Zurano JP; Mazzitelli B; Scruzzi G; Barbero P; Cardozo D; Gallego S; Borda M; Diaz M; ; ; Ridao F; Rosales AB; ; Bhon J; Talia JM; Diangelo ME; Lacaze MA; ; Aime B; Gutierrez SI; Ercole R; Toro R; Tau L; Delaplace L; Compagnucci MF; ; Sartori C; Desimone I; Echegoyen C; Velazquez P; Testa C; ; Hozbor D; Docena G; Laino CH; Kreplak N; Pifano M; Barbas G; Rearte A; Vizzotti C; Castelli JM; Geffner J; Gamarnik AV
Cell Rep Med; 2022 Aug; 3(8):100706. PubMed ID: 35926505
[TBL] [Abstract][Full Text] [Related]
10. BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.
Kaznadzey A; Tutukina M; Bessonova T; Kireeva M; Mazo I
Front Immunol; 2022; 13():797918. PubMed ID: 35493476
[TBL] [Abstract][Full Text] [Related]
11. Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients.
Tomas-Grau RH; Maldonado-Galdeano C; López MA; Pingitore EV; Aznar P; Alcorta ME; Del Mar Vélez EM; Stagnetto A; Soliz-Santander SE; Ávila CL; Socias SB; Costas D; Chahla RE; Perdigón G; Chehín RN; Ploper D; Cazorla SI
Aging (Albany NY); 2022 Sep; 14(18):7193-7205. PubMed ID: 36152043
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
Kang CM; Lee NY; Lin CH; Hsu YS; Chang YC; Chung MY; Lee YF; Tseng WP; Wu JL; Chen SY; Lu MC; Ko WC; Lee PI; Hsueh PR
J Clin Virol; 2022 Jun; 150-151():105156. PubMed ID: 35413588
[TBL] [Abstract][Full Text] [Related]
14. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
15. Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V.
Claro F; Silva D; Pérez Bogado JA; Rangel HR; de Waard JH
Int J Infect Dis; 2022 Sep; 122():850-854. PubMed ID: 35690364
[TBL] [Abstract][Full Text] [Related]
16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
[TBL] [Abstract][Full Text] [Related]
18. Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination.
Astakhova EA; Byazrova MG; Yusubalieva GM; Kulemzin SV; Kruglova NA; Prilipov AG; Baklaushev VP; Gorchakov AA; Taranin AV; Filatov AV
Cells; 2022 Jun; 11(13):. PubMed ID: 35805076
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination.
Mojadadi MS; Javadinia SA; Attarian F; Samami E; Sobhani M
Front Public Health; 2022; 10():960598. PubMed ID: 36711369
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]